| abstract |
The present invention relates to new CGRP antagonists of the general formula I, in which R1, R2, R3, Ra, Rb, Rc, X, Y, and Z are defined as mentioned below, individual diastereomers thereof, individual enantiomers thereof, and salts thereof, in particular physiologically acceptable salts thereof having inorganic or organic acids or bases, drugs containing said compounds, use thereof, and method for the production thereof. |